Clinical trial
A Phase 2 Multi-Center, Open Label Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in Newly Diagnosed, Transplant Eligible Multiple Myeloma
NCT04786028 is registered in ClinicalTrials.gov with Canadian Myeloma Research Group as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Multi-Center, Open Label Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in Newly Diagnosed, Transplant Eligible Multiple Myeloma
- Lead sponsor
- Canadian Myeloma Research Group
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- December 8, 2021
- Completion date
- June 30, 2027
- Enrollment
- 72 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.